1. Home
  2. NRO vs STTK Comparison

NRO vs STTK Comparison

Compare NRO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman Real Estate Securities Income Fund Inc.

NRO

Neuberger Berman Real Estate Securities Income Fund Inc.

HOLD

Current Price

$3.04

Market Cap

199.6M

Sector

Finance

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.68

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRO
STTK
Founded
2003
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.6M
119.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NRO
STTK
Price
$3.04
$3.68
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$4.00
AVG Volume (30 Days)
239.4K
473.4K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
11.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.51
$0.69
52 Week High
$3.45
$3.79

Technical Indicators

Market Signals
Indicator
NRO
STTK
Relative Strength Index (RSI) 54.56 79.33
Support Level $2.91 $3.15
Resistance Level $3.06 $3.29
Average True Range (ATR) 0.03 0.22
MACD 0.02 0.03
Stochastic Oscillator 83.33 91.24

Price Performance

Historical Comparison
NRO
STTK

About NRO Neuberger Berman Real Estate Securities Income Fund Inc.

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: